A Randomized, Double-blind, Controlled, Parallel-group, Single Dose, Three arm Study to Compare the Pharmacokinetic Similarity of MAB-22 Versus Prolia® Sourced from the European Union and United States in Healthy Male Participants

2023-509749-11-00 Protocol MAB-22-101 Human pharmacology (Phase I) - Bioequivalence study Ended

Start 5 Jun 2024 · End 23 Jul 2025 · Status Ended · 2 EU/EEA countries · 2 sites · Protocol MAB-22-101

Overview

Sponsor-declared trial summary

Phase Human pharmacology (Phase I) - Bioequivalence study
Status Ended
Participants planned 225
Countries 2
Sites 2

Healthy volunteers

Key facts

Sponsor
Xentria Inc.
Participant type
Healthy volunteers
Age range
18-64 years
Gender
Male
Therapeutic area
Diseases [C] - Musculoskeletal Diseases [C05]
Trial duration
5 Jun 2024 → 23 Jul 2025
Decision date (initial)
2024-06-04
Transition trial
No
Low-intervention
No
Rare-disease indication
No
Vulnerable population
No

Trial design

CTIS Part I — objectives, methods, condition coding

Conditions and MedDRA coding

Healthy volunteers

VersionLevelCodeTermSystem organ class
20.0 PT 10031282 Osteoporosis 100000004859

Sponsors and contacts

Sponsor organisations, regulatory contacts, third parties

Xentria Inc.

Sponsor organisation
Xentria Inc.
Address
2032 North Clybourn Avenue Suite 100
City
Chicago
Postcode
60614-4051
Country
United States

Scientific contact point

Organisation
Xentria Inc.
Contact name
Tom Matthews

Public contact point

Organisation
Xentria Inc.
Contact name
Noopur Singh

Locations

2 EU/EEA countries · 2 investigational sites

By country

CountryMS statusPlanned subjectsSites
Hungary Ended 117 1
Netherlands Ended 108 1
Rest of world 0

Investigational sites

Hungary

1 site · Ended
Pharmaceutical Research Associates Magyarorszag
PRA Klinikai Farmakológiai Vizsgálóhely, Rottenbiller Utca 13, 1077, Budapest

Netherlands

1 site · Ended
Pharmaceutical Research Associates Group B.V.
Program Management, Van Swietenlaan 6, 9728 NZ, Groningen

Country notifications

Trial-start, recruitment-start, end and early-termination notifications submitted per Member State

Country Trial startTrial end Recruitment startRecruitment end Early termination
Hungary 2024-06-14 2025-07-22 2024-06-14 2024-11-12
Netherlands 2024-06-05 2025-07-17 2024-06-05 2024-11-07

Application history

5 submissions — initial application plus substantial / non-substantial modifications

#TypeCodeSubmittedReference MSConclusionDecision date
1 INITIAL IN 2024-03-04 Netherlands Acceptable
2024-05-30
2024-05-30
2 SUBSTANTIAL MODIFICATION SM-1 2024-07-23 Netherlands Acceptable
2024-09-02
2024-09-02
3 NON SUBSTANTIAL MODIFICATION NSM-2 2024-10-31 Netherlands Acceptable
2024-09-02
2024-10-31
4 SUBSTANTIAL MODIFICATION SM-2 2025-06-13 Netherlands Acceptable
2025-07-21
2025-07-22
5 NON SUBSTANTIAL MODIFICATION NSM-4 2025-08-18 Netherlands Acceptable
2025-07-21
2025-08-18